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Abstract We report on a new, sensitive, and fast LC-
MS/MS method for the simultaneous determination of
25 key sphingolipid components in human plasma, in-
cluding phosphorylated sphinganine and sphingosine, in
a single 9-min run. This method enables an effective
and high-throughput coverage of the metabolic changes
involving the sphingolipidome during physiological or
pathological states. The method is based on liquid–liq-
uid extraction followed by reversed-phase LC-MS/MS.
Exogenous odd-chain lipids are used as cost-effective
but reliable internal standards. The method was fully
validated in surrogate matrix and naive human plasma
following FDA guidelines. Sample stability and dilution
integrity were also tested and verified.
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Introduction
Sphingolipids are a class of bioactive lipid molecules charac-
terized by a high degree of structural and functional diversity.
They have been implicated in a variety of biological process-
es, including senescence [1], inflammation [2], and apoptosis
[3, 4]. Furthermore, the plasma levels of these compounds
may be altered in age-related disorders such as Alzheimer’s
disease [5, 6] and mild cognitive impairment [7].
Sphingolipids also play important roles in cancer [8], diabetes
[9], skin disease [10], atherosclerosis [11], and the pathogen-
esis of obesity [12]. Given their varied and important func-
tions in health and disease, it is essential to be able to measure
the concentrations of these biomolecules in plasma and tissues
with sensitive, accurate, and reliable methods. Moreover, be-
cause of the tight metabolic interconnections among different
members of the sphingolipid family, it is important to perform
such measurements simultaneously on multiple rather than
individual components of the family. Key products and inter-
mediates in sphingolipid metabolism are illustrated in Fig. 1.
In the de novo synthesis pathway, sphinganine is acylated to
form dihydroceramides, which are converted into ceramides
by the action of a desaturase. Ceramides and their correspond-
ing sphingomyelins are metabolically connected through
sphingomyelin synthase, which catalyzes the transfer of a po-
lar choline head group onto the relatively apolar structure of
ce ramides . The reve r se reac t ion , ca t a lyzed by
sphingomyelinase, represents the so-called Bsalvage pathway^
for ceramide formation [13]. Glucosyl- and galactosyl-
transferases converts ceramides into glucosylceramides and
galactosylceramides, respectively. Sphingosine and
sphinganine (SPH d18:1 and SPH d18:0) are phosphorylated
by the action of various kinases. The signaling functions of
sphingosine-1-phosphate (S1P d18:1), in particular, are cur-
rently under extensive investigation since the discovery in
1998 that S1P d18:1 is an extracellular ligand for S1PR1
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receptors [14] involved in cancer development and immune
responses. An important role in kidney protection after hepatic
ischemia has also been recently proved for sphinganine-1-
phosphate (S1P d18:0) [15]. These evidences underscore the
need for analytical tools, allowing the simultaneous detection
of SPH d18:1, SPH d18:0, and their corresponding phosphate
analogues, along with the other major members of this lipid
class like ceramides and sphingomyelins. A variety of techni-
cal approaches have been reported for the quantification of
sphingolipids in biological matrices. These include thin-layer
chromatography (TLC) [16], high-performance liquid chro-
matography (HPLC) [17], enzymatic hydrolysis followed by
HPLC [18], and immunological assays [19]. In recent years,
LC-MS/MS-based methods largely imposed themselves over
other approaches [20–24]. However, most of these LC-MS/
MS methods suffer from substantial disadvantages, which in-
clude low throughput [22], lack of full validation [10, 24], or
incomplete analytical coverage (e.g., sphingomyelins) [25].
Substantial advances in lipidome investigation have also been
made with shotgun-like workflows, either using combined
precursor or neutral loss scan modes [26] or in scan mode
using high-resolution instruments [27], but triple–quadru-
pole-based, targeted approaches will still represent the refer-
ence tools for clinical applications in the near future. In this
field, indeed, robustness, high-throughput, and easiness of the
procedures are the most important benchmarks. The simulta-
neous analysis of the sphingolipid metabolism (Fig. 1) is ex-
tremely challenging due to the structural heterogeneity of the
sphingolipidome and the broad polarity span of its members.
Differences in polarity, for example, make it difficult to group
together S1P d18:1 (LogP=3.43) and Cer d18:1/24:0 (LogP=
14.42) in the same sample preparation and the same chromato-
graphic run. Even more challenging is to achieve their effi-
cient separation in a short analysis time, ensuring at the same
time robustness, reproducibility, and sensitivity. Several new
sample preparation methods have also been established like
dried blood spot extraction [28] and solid-phase extraction
followed by in situ derivatization [29]. Despite these ad-
vances, the well-known Bligh-Dyer [30] total lipid extraction
still remains very popular, thanks to its efficacy and ease.
Here, we describe an LC-MS/MS method for the simulta-
neous identification and quantification of 25 key members
of the sphingolipidome in human plasma, including S1P
d18:1 and S1P d18:0. To our knowledge, this is the first re-
ported LC-MS/MSmethod suitable for the simultaneous eval-
uation of the large majority of sphingolipid class representa-
tives, and most importantly, this is the first report of an effec-
tive incorporation of sphingosine and sphinganine phosphates
in a reversed-phase method focused on ceramides and
sphingomyelins. The method is sensitive and robust, and it
Fig. 1 Key products and intermediates in human sphingolipidome
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has been validated following FDA guidelines, testing for re-




Sphingolipid standards were purchased from Avanti Polar
Lipids (Alabaster, Alabama USA). Solvents and chemicals
were from Sigma-Aldrich (Milan, Italy). UPLC/MS and MS/
MS systems and columns were from Waters (Milford, USA).
Human plasma samples
Healthy male and female subjects were enrolled in the MCI/
AD Italian prevention project [31, 32] aimed at studying cog-
nitive and neuropsychiatric symptoms and disorders in pa-
tients with MCI and AD at the IRCCS Santa Lucia
Foundation memory clinic in Rome, Italy. The nature and
purpose of the study were presented to patients and caregivers
and controls, and written informed consent was obtained. The
study was approved by the Ethical Committee of the Santa
Lucia Foundation. Human plasma samples were collected
from healthy male and female volunteers of all ages. Blood
samples were taken by venipuncture in the morning after an
overnight fast. Blood was collected into 10 ml tubes contain-
ing spray-coated K2EDTA (Vacutainer, Becton Dickinson,
Italy). Plasma was then prepared by centrifugation of blood
at 400×g for 15 min, then stored at −80 °C before analysis.
Blood drawing and sample preparation of human plasma sam-
ples were carried out applying the best safety precautions.
Plasma samples from all subjects were then pooled together
and used as naïve matrix for the present study.
Stock solution preparation
Stock solutions were prepared in methanol and chloroform
mixture (1:1). An internal standard (IS) solution (200 nM
Cer d18:1/17:0, 200 nM PC 23:0/23:0, 200 nM GlcCer
d18:1/12:0, 250 nM SPH d17:1, 250 nM SPH d17:0,
250 nM S1P d17:1, and 250 nM S1P d17:0) was prepared
by spiking the corresponding standards in the extraction sol-
vent methanol/chloroform (2:1) added with trifluoroacetic ac-
id (TFA) to a final 0.1 % (v/v) concentration.
Sample preparation
Samples were extracted using a Bligh andDyer method for lipid
extraction [30]. Calibration curve (CC), quality control (QC), or
test samples (50 μL) were transferred to glass vials. Liquid–
liquid extraction (LLE) was carried out using a 1:2 by volume
chloroform/methanol mixture (2 ml) added with TFA (final
0.1 % v/v) and spiked with the IS as described above. After
mixing for 30 s with a Vortex®, chloroform (0.5 mL) and water
(0.5 mL) were sequentially added, thoroughly mixing after each
addition. The samples were then centrifuged for 15 min at
3500×g at room temperature. At the end of the process, the
aqueous (upper) and organic (lower) phases were separated by
a protein precipitate floating at the interface. The organic phase
was then transferred to glass vials. To increase the overall re-
covery, the aqueous fraction was extracted again with chloro-
form (1 mL). The two resulting organic phases were pooled,
dried under a stream of N2, and the residues were redissolved
in methanol/chloroform (9:1, by volume; 0.1 mL). After mixing
(30 s) and centrifugation (10min at 5000×g, room temperature),
the samples were transferred to glass vials for analyses.
LC-MS/MS analyses
LC-MS/MS analyses of the samples were carried out on an
Acquity UPLC system coupled with a Xevo TQ-MS triple-
quadrupole mass spectrometer. Chromatographic separation
was achieved using a BEH C18 column (2.1×50 mm, 1.7 mi-
cron particle size) eluted at a flow rate of 0.4 mL/min.
Instruments and column were from Waters Inc. Milford, MA,
USA. The mobile phase consisted of 0.1 % formic acid in
acetonitrile/water (20:80 v/v) as solvent A and 0.1% formic acid
in acetonitrile/2-propanol (20:80 v/v) as solvent B. A step gra-
dient program was developed for the best separation of all me-
tabolites: 0.0–1.0 min 30 % B, 1.0–2.5 min 30 to 70 % B, 2.5–
4.0 min 70 to 80 % B, 4.0–5.0 min 80 % B, 5.0–6.5 min 80 to
90 % B, and 6.6–7.5 min 100 % B. The column was then
reconditioned to 30 % B for 1.4 min. The total run time for
analysis was 9 min, and the injection volume was 3 μL. The
mass spectrometer was operated in the positive ESI mode, and
analytes were quantified by multiple reaction monitoring
(MRM). The capillary voltage was set at 3 kV. The cone voltage
was set at 25 V for all transitions, except for some SM. The
complete panel of source parameters and MRM transitions are
reported in the datasheet in the Electronic Supplementary
Material (ESM). The source temperature was set to 120 °C.
Desolvation gas and cone gas (N2) flow were set to 800 and
20 l/h, respectively. Desolvation temperature was set to 600 °C.
Data were acquired by MassLynx software and quantified by
TargetLynx software. Calibration curves were constructed by
plotting the analyte to IS peak areas ratio versus the correspond-
ing analyte concentration using weighted (1/x2) least square re-
gression analysis, as recommended by Gu and colleagues [33].
Standard curves
As analytes are present endogenously in plasma, 5 % bovine
serum albumin (BSA) in saline solution was used as surrogate
matrix [34] for the first part of the validation process (see the
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BResults and discussion^ for additional information).
Calibration standards were prepared by spiking the analytes
in the surrogate matrix. Eight-point calibration curves (1 to
1000 nM) were prepared by serial dilution into saline solution
containing 5 % BSA.
Quality control samples
Quality control samples were prepared at three different
levels, as low QC (LQC), medium QC (MQC), and high QC
(HQC), using the same procedure described for the standard
curve to final concentrations of 19.5, 260, and 650 nM,
respectively.
Linearity, precision, and accuracy
Method linearity was tested using the eight-point calibration
curve described above. The overall method performance was
assessed by evaluating the accuracy and precision of back-
calculated concentrations of standards and evaluating the
slope, intercept, and coefficient of determination of the 1/(con-
centration)2 weighted regression line. Following FDA guide-
lines in this matter, acceptance criteria for the calibration curve
were set to ±15 % of the nominal concentration and six out of
eight calibration points had to meet the acceptance criteria.
Precision and accuracy were determined by assessing the per-
formance of quality control samples (LQC=19.5 nM, MQC=
260 nM, and HQC=650 nM). All the QC samples were run in
triplicate. Accuracy was evaluated by calculating the percent
deviation (% dev.) from nominal concentration. Precision was
determined by calculating the coefficient of variation (% CV)
of replicates within each batch. Acceptance criteria for preci-
sion and accuracy were defined as ≤15 % [35].
LLOQ
The lower limit of quantification for our method was set to
1 nM for all analytes. At this value, all species showed a S/N
value above 10. Six replicate 1-nM calibrators spiked in 5 %
BSAwere extracted and analyzed. The obtained %CV values
for each analyte are reported in the ESM (supplementary
datasheet).
Sample recovery and matrix effects
Recovery and matrix effects were evaluated using the method
outlined by Matuszewski et al. [36]. Three sets of samples
were prepared spiking the standards at three different concen-
trations. Set 1 consisted of neat samples (standards spiked in
reconstitution solution). Set 2 consisted of post-extraction
spiked samples (blank matrix was extracted and then spiked
with standards). Set 3 consisted of normal extracted samples
(standards were spiked in blank matrix and then extracted).
Matrix effect (ME) was calculated as (set 2/set 1)×100.
Recovery (RE) was calculated as (set 3/set 2)×100. Human
plasma matrix effect was evaluated using the post-column
infusion method: A mixture of analytes diluted in 9:1
MeOH/CHCl3 to a final 10 μM concentration was infused
post-column in the LC-MS/MS system using a tee union.
Repeated injections of extracted human plasma samples were
performed in the systemwith the aim to investigate significant
decreases or increases in the analyte MRM ion currents.
Plasma recovery
Analyte recovery from plasma was calculated using the same
criteria described above: A mixture of standards was added at
different concentrations in plasma (from 50 nM to 15 μM)
prior or after the extraction (pre- and post-extraction spiking).
The recovery was calculated as the ratio between the analyte
peak area pre-spiked in plasma and the analyte peak area in
post-extraction spiked samples (see BResults and discussion^
for detailed information).
Autosampler and plasma stability and dilution integrity
Plasma stability was assessed by spiking odd-chain standards
in human plasma and keeping the sample under different tem-
perature and timing conditions: short-term conditions (4 and
25 °C for 6 h) and long-term storage conditions (−20 ° C for
9 days). Sample stability in the instrument autosampler was
also evaluated by re-analyzing extracted samples kept under
the autosampler condition (18 h at 4 °C). All the stability
studies were conducted in triplicate at 500 nM concentration.
Method integrity to dilutions was also evaluated by spiking
odd-chain standards in human plasma to a final 4000 nM con-
centration. Samples were then diluted 20-fold in blank human
plasma, extracted, and analyzed.
Results and discussion
Chromatographic separation
We tested multiple combinations of stationary phases and elu-
tion conditions and eventually selected a gradient elution with
an initial solvent system of low organic content, which was
required to retain on the column polar compounds such as
SPH d18:1 and SPH d18:0, followed by a rapid progressive
increase in solvent strength, which was needed to elute from
the column apolar compounds such as ceramides and
dihydroceramides. The best compromise between selectivity
and speed of separation was obtained using a C18 stationary
phase and a high content of 2-propanol (80 %) in solvent B
coupled to 20 % ACN in solvent A to reduce back pressure.
Using these conditions, an adequate separation of 25 target
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analytes was achieved in a single 9-min-long LC-MS run
(Fig. 2). In the interest of clarity, the analyte traces shown in
Fig. 2 are split in four panels (A: separation of ceramides; B:
dihydroceramides; C: sphingomyelins, SPH d18:1, SPH
d18:0, S1P d18:1, and S1P d18:0; D: glucosylceramides).
MS parameter optimization and choice of internal standards
To define MS parameters for optimum sensitivity, authentic
standards were infused separately into the mass spectrometer.
The most intense MRM transition was selected to quantify
each analyte (see ESM supplementary datasheet). A total of
32MRM transitions were included in the method. Although it
is very well known that deuterated standard represents the best
choice as internal standards for LC-MS/MS analysis of endog-
enous molecules since a very limited number of deuterated
sphingolipids are commercially available, and due to the very
high cost of the custom synthesis of a deuterated standard for
each of the 25 sphingolipids we are tracking, we were forced
to set up and validate our method using odd-chain lipids as
internal standards for analytes of similar structure but with
even-numbered carbon chains. The use of odd-chain standards
is a very common approach for sphingolipid analysis [37], and
odd-chain Cer d18:1/17:0 has already been successfully used
by Haus and colleagues to determine ceramide content in
plasma [9]. Since no odd-chain glucosylceramides are com-
mercially available, we used instead the short-chain GlcCer
d18:1/12:0, which was not detectable in plasma. It is
important to point out that our RP method cannot distinguish
between gluco- and galactosylceramides that are fully
coeluting. We then chose to use glucosylceramides for the
calibration curve and GlcCer d18:1/12:0 as internal standard
for both gluco- and galacto- derivatives, assuming an identical
instrumental response in ESI conditions, as recently con-
firmed by Shaner and colleagues [38]. For the same reason
(full coelution and identical instrumental response) and to
limit additional costs, we only used glucosylceramides in the
calibration curve. Our method is then intended to evaluate the
total hexosylceramides content in plasma. Notably, SM d18:1/
17:0 did not provide a suitable internal standard for endoge-
nous sphingomyelin species because its MRM transition (m/z
718->184) was found to generate an interfering peak (Fig. 3).
Having excluded other options, we then concluded that SM
d18:1/17:0 is endogenously present in plasma and we tested
other exogenous lipid molecules potentially suitable as inter-
nal standards for sphingomyelins (see ESM Fig. S1). We test-
ed human plasma for the MRM transitions of PC 16:0/16:0
(used by Byrdwell and Perry [39]), SM d18:1/12:0, PC 9:0/
9:0, PC 15:0/15:0, and PC 17:0/17:0 (panels A to E, respec-
tively). All these transitions generated huge ion currents
(>5000–10,000 ion counts) at multiple retention times.
These peaks correspond to isomeric (even/even) phosphati-
dylcholines like, for example, (16:0/18:0) for (17:0/17:0).
We then discarded all the corresponding molecules as internal
standards. The best alternative option would have been an
(odd/even) phosphatidylcholine that is not commercially
Fig. 2 MRM chromatograms of A ceramides; B dihydroceramides; C sphingomyelins, sphingosines, and sphinganines; and D glucosylceramides
spiked at 1 μM in 5 % BSA
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available. We then opted for PC 23:0/23:0 because the corre-
sponding MRM transition from human plasma (ESM Fig. S1,
panel F, black trace) generates the lowest ion current (<1500
ion counts) and does not interfere with the detection and quan-
tification of authentic PC 23:0/23:0 (red trace).
A detailed summary of the MRM transitions and source
parameters for all analytes and internal standards is reported
in the ESM (supplementary datasheet). Since we are fully
aware that the lack of a coeluting internal standard might
represent a major problem in LC-MS/MS, we did our best to
evaluate possible matrix effects using the post-column infu-
sion method [40]. The results of this experiment are available
for download as ESM. Most analytes did not show any rele-
vant matrix effect when extracted human plasma samples
were injected. Five analytes showed non-negligible matrix
effects with three out of four glucosylceramides among them
(16:0, 18:0, and 18:1). It is thus important to point out that,
assuming identical matrix effects for galactosylceramides, the
evaluation of hexosylceramides content in plasma might be
affected, in the absence of commercially available deuterated
standards. As expected, injections of extracted plasma caused
a positive increase in the post-column infusion trace of those
metabolites that are endogenously present in plasma at micro-
molar concentrations (sphingomyelins mostly). We also in-
vestigated the possibility of endogenous plasma phosphatidyl-
cholines coeluting with the four sphingomyelins quantified by
our method and having similar m/z values. For the same rea-
sons indicated above (common 184m/z fragment), this would
result in interferences and inaccuracy in sphingomyelins
quantification. We addressed this issue by means of high-
resolution MS, a brute formula calculation software and
LipidMaps database search, and we showed that, at the reten-
tion time of the four sphingomyelins targeted by our method,
no phosphatidylcholines having a m/z value close to that se-
lected for fragmentation (±0.5m/z units) is coeluting. The re-
sults of this experiment, along with a detailed description of
the experiment, are available for download as ESM.
Sample preparation
Sphingolipids are naturally present in plasma, where they can
reach relatively high concentrations (10–20 μM for certain
species). This hindered the use of plasma as blank analytical
matrix and interfered with our ability to validate the method.
Since depletion strategies (for example, using charcoal [41,
42]) did not perform well in our hands, we switched to a
surrogate plasma-like matrix constituted of a saline solution
containing diluted, lipid-free, bovine serum albumin (BSA,
5 g/0.1 L), which has been widely used in the past to mimic
plasma in bioanalysis [43–45]. We fully validated the method
using this artificial matrix. Linearity, accuracy, precision, ma-
trix effect, and recovery were evaluated for each analyte. Full
validation data are available for download as ESM. Next, we
determined linearity and recovery in human plasma samples.
We first used odd-numbered chain internal standards and
GlcCer(d18:1/12:0) to test process efficiency: Different com-
binations of analytes to extraction solution (ES) volume ratios
were examined. We found that while a 1:6 ratio was adequate
for 5 % BSA, a 1:40 ratio was required to ensure a good
recovery from plasma. We then focused on S1P(d18:1) and
S1P(d18:0), where the hydrophilic/hydrophobic dichotomy of
sphingolipids is particularly relevant. At neutral pH, these
molecules have a positively charged amino group and a neg-
atively charged phosphate group, along with a 14 carbon long
aliphatic chain. Without changes in the pH, the extraction
efficiency of S1P(d18:1) and S1P(d18:0) from plasma is rath-
er low (approximately 20 % for both) with a large fraction
(>75 %) of analyte that remains in the upper aqueous phase.
We then added TFA to the extraction solvent (0.1 % in vol-
ume) to force the protonation of both the phosphate group and
the amino group, reducing the span in the protonation states.
The trifluoroacetate anion also served as ion-pairing agent.
TFAwas chosen due to its volatility. This expedient increased
the recovery of S1P(d18:1) and S1P(d18:0) to more than 80%
Fig. 3 MRM trace for transition m/z 718->184 from standard SM d18:1/
17:0 (A) and from extracted naïve plasma (B). An interfering peak in
plasma shares the same transition and retention time with standard SM
d18:1/17:0
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and had no significant effect on the recovery of other species.
With this information in hand, to obtain a more complete
picture of the extraction efficiencies from human plasma for
all analytes, we prepared a set of human plasma samples
spiked with higher-than-background concentrations of stan-
dards (from 50 nM to 15 μM). Plasma samples were also
extracted, analyzed, and considered as background level. We
then plotted the sphingolipids concentration against the total
amount of standards added. The amount of sphingolipids nat-
urally present in the naïve samples was subtracted from each
point of the graph. Results are reported in Fig. 4. As shown in
the graphs, the method yields linear recoveries when applied
to human plasma samples. Furthermore, in order to calculate
the plasma recovery values for individual analytes, each point
was prepared using both pre-extraction and post-extraction
spiking for each analyte. The recovery was then calculated
from the ratio between pre-extraction and post-extraction
spiking. Table 1 shows the averaged recovery values from
surrogate matrix and human plasma for each sphingolipid
class. The full data panel, with data on individual species,
may be found in the ESM (Supplementary Datasheet).
Linearity, precision, accuracy, carryover, stability, and dilution
integrity
Our method showed a very good linearity over a 103-fold
range (1–1000 nM, eight calibration points) with an r2 value
of 0.9895–0.9973 using 5 % BSA as matrix and 0.9947–
1.0000 using human plasma as matrix. A signal-to-noise ratio
(S/N) of ≥10 was considered as lowest limit of quantification
to determine method sensitivity, although for most analytes
the S/N at 1 nM was higher than 10. For this reason, lower
limit of quantification (LLOQ) from 5%BSAwas set to 1 nM.
At this concentration, all analytes showed a %CV below 20%
(see ESM, supplementary datasheet). Precision and accuracy
were also determined in 5 % BSA, assessing the performance
of three quality control samples (LQC=19.5 nM, MQC=
260 nM, and HQC=650 nM). Accuracy was evaluated by
calculating the percent deviation from nominal concentra-
tions. Precision was determined by calculating the coefficient
Fig. 4 The plots shows the analyte concentration calculated after extraction and LC-MS/MS analysis versus the amount of authentic standard
sphingolipids added to naïve plasma. Pre-spiking naïve plasma levels were considered as background levels and subtracted
Table 1 Recovery values by sphingolipid class (mean±standard
deviation) from 5 % BSA and from human plasma samples
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of variation of replicates within each batch. All the QC sam-
ples were run in triplicate. Acceptance criteria for precision
and accuracy were defined as ≤15 % [35]. Intra- and inter-
assay precision and accuracy were also tested by analyzing the
same QC samples. The full dataset is reported in the ESM
(supplementary datasheet). Furthermore, in order to evaluate
carryover, a blank sample was injected immediately after the
highest standard. Since some carryover was observed with the
usual water/methanol/ACN/2-propanol needle washing sys-
tem, we used acetonitrile/water (1:1) containing 10 % acetone
as needle wash solvent. With this expedient, no significant
carryover was observed for any of the analytes (less than
0.5 %). Analyte stability evaluation was also included in the
experimental layout: Odd-chain standards were spiked in
naïve human plasma to a final 500 nM concentration (tripli-
cate samples) and tested for stability in both short-term (4 and
25 °C for 6 h) and long-term conditions (9 days at −20 °C).
The stability of extracted samples in the instrument
autosampler conditions (4 °C for 6 h) was also evaluated.
Analytes are stables in all the abovementioned conditions
(our acceptance criteria were set to ±15 % of nominal concen-
tration). Since sphingolipids are present in human plasma at
very different concentrations (from low nM to high μM), we
also tested the dilution integrity of our method in order to be
able to confidently quantify samples above the upper limit of
the calibration curve. We then spiked odd-chain standards in
naïve human plasma at a final 4 μM concentration, and we
diluted the samples 20-fold using naïve human plasma. After
sample extraction and analysis, analyte concentrations were
calculated using the appropriate multiplication factor. Results
demonstrate that our method is tolerant to 20-fold dilution
since the calculated concentrations were within the acceptance
criteria (precision 0.16–4.82 %, accuracy 83.04–94.25 %).
Data on stability and dilution integrity are reported in the
ESM (supplementary datasheet). All the sphingolipids that
were detected and quantified with our method in naïve human
plasma are reported in the supplementary datasheet in the
ESM.
Conclusions
In the present report, we describe a new LC-MS/MS method
that allows for the rapid identification and quantification of 25
key sphingolipid species in human plasma, including S1P
d18:1 and S1P d18:0. We proved that a LogP span of more
than 10 units (from 3.43 of S1P d18:1 to 14.42 of Cer d18:1/
24:0 can be efficiently explored in a single sample preparation
and LC-MS run. While other validated methods for the LC-
MS/MS quantification of sphingolipids are available in the
literature, none of them offers a comparable level of analyte
coverage, rapidity, and validation. For example, Bui et al. [25]
describe a 5-min separation but do not cover sphingomyelins;
Kasumov and colleagues [22] describe a separation of seven
species in 15 min. Other methods, though validated, offer an
even more limited analyte coverage: Cer d18:1/22:0 and Cer
d18:1/24:0 [23] or seven species by nano-LC/MS [21]. The
method we propose here is sensitive, linear, robust, and very
rapid (9 min per run). Although it suffers from some matrix
effect that cannot be fully compensated by the use of odd-
chain internal standards, we managed to evaluate this effect
and control it, achieving very promising results from human
plasma. Future implementations of this method with custom-
made deuterated internal standards will hopefully improve the
overall method performance, making it suitable for clinical
routine. The huge costs for custom synthesis will surely be
compensated by the final outcome on health-care systems
since sphingolipids and phosphorylated sphingolipids have
been proposed as biomarkers for various pathological condi-
tions. The potential of the method presented here is manifested
as it permits a complete and reliable analysis of the full
sphingolipid core metabolism in less than 10 min.
Furthermore, in addition to the whole sphingolipids panel,
the possibility to track S1P d18:1 and S1P d18:0 in plasma
could be of great importance for clinical research on cancer
and immune system disorders.
Acknowledgments The authors would like to thank Dr. Gianfranco
Spalletta (IRCCS Santa Lucia, Rome, Italy) for kindly providing human
plasma samples from healthy donors. The financial support of the Na-
tional Institutes of Health (grants DK073955 and DA012413 to D.P.) is
gratefully acknowledged.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Webb LM, Arnholt AT, Venable ME (2010) Phospholipase D mod-
ulation by ceramide in senescence.Mol Cell Biochem 337(1–2):153–
158
2. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De
Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy
G, Schmid KW, Weller M, Tümmler B, Lang F, Grassme H, Döring
G, Gulbins E (2008) Ceramide accumulation mediates inflammation,
cell death and infection susceptibility in cystic fibrosis. Nat Med
14(4):382–391
3. Posse de Chaves EI (2006) Sphingolipids in apoptosis, survival and
regeneration in the nervous system. BiochimBiophys Acta 1758(12):
1995–2015
4. YoungMM, Kester M,Wang HG (2013) Sphingolipids: regulators of
crosstalk between apoptosis and autophagy. J Lipid Res 54(1):5–19
5. He X, Huang Y, Li B, Gong CX, Schuchman EH (2010)
Deregulation of sphingolipid metabolism in Alzheimer’s disease.
Neurobiol Aging 31(3):398–408
5196 A. Basit et al.
6. Mielke MM, Haughey NJ, Bandaru VV, Weinberg DD, Darby E,
Zaidi N, Pavlik V, Doody RS, Lyketsos CG (2011) Plasma
sphingomyelins are associated with cognitive progression in
Alzheimer’s disease. J Alzheimers Dis 27(2):259–269
7. Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick
R, Carlson MC, Mori S, Miller MI, Ceritoglu C, Brown T, Albert M,
Lyketsos CG (2010) Plasma ceramides are altered in mild cognitive
impairment and predict cognitive decline and hippocampal volume
loss. Alzheimers Dement 6(5):378–385
8. Bieberich E (2008) Ceramide signaling in cancer and stem cells.
Futur Lipidol 3(3):273–300
9. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo
RA, Kirwan JP (2009) Plasma ceramides are elevated in obese sub-
jects with type 2 diabetes and correlate with the severity of insulin
resistance. Diabetes 58(2):337–343
10. Farwanah H, Pierstorff B, Schmelzer CE, Raith K, Neubert RH,
Kolter T, Sandhoff K (2007) Separation andmass spectrometric char-
acterization of covalently bound skin ceramides using LC/APCI-MS
and Nano-ESI-MS/MS. J Chromatogr B Anal Technol Biomed Life
Sci 852(1–2):562–570
11. Bismuth J, Lin P, Yao Q, Chen C (2008) Ceramide: a common path-
way for atherosclerosis? Atherosclerosis 196(2):497–504
12. Samad F, Hester KD, Yang G, Hannun YA, Bielawski J (2006)
Altered adipose and plasma sphingolipid metabolism in obesity: a
potential mechanism for cardiovascular and metabolic risk. Diabetes
55(9):2579–2587
13. Kitatani K, Idkowiak-Baldys J, Hannun YA (2008) The sphingolipid
salvage pathway in ceramide metabolism and signaling. Cell Signal
20(6):1010–1018
14. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G,
Desale H, Clemons B, Cahalan SM, Schuerer SC, Sanna MG, Han
GW, Kuhn P, Rosen H, Stevens RC (2012) Crystal structure of a lipid
G protein-coupled receptor. Science 335(6070):851–855
15. Park SW, Kim M, Chen SW, Brown KM, D’Agati VD, Lee HT
(2010) Sphinganine-1-phosphate protects kidney and liver after he-
patic ischemia and reperfusion in mice through S1P1 receptor acti-
vation. Lab Investig 90(8):1209–1224
16. Bruce CR, Thrush AB, Mertz VA, Bezaire V, Chabowski A,
Heigenhauser GJ, Dyck DJ (2006) Endurance training in obese
humans improves glucose tolerance and mitochondrial fatty acid
oxidation and alters muscle lipid content. Am J Physiol Endocrinol
Metab 291(1):E99–E107
17. Yano M, Kishida E, Muneyuki Y, Masuzawa Y (1998) Quantitative
analysis of ceramide molecular species by high performance liquid
chromatography. J Lipid Res 39(10):2091–2098
18. Lee S, Lee YS, Choi KM, Yoo KS, Sin DM, KimW, Lee YM, Hong
JT, Yun YP, Yoo HS (2012) Quantitative analysis of sphingomyelin
by high-performance liquid chromatography after enzymatic hydro-
lysis. Evid Based Complement Alternat Med 2012:396218
19. Cowart LA, Szulc Z, Bielawska A, Hannun YA (2002) Structural
determinants of sphingolipid recognition by commercially available
anti-ceramide antibodies. J Lipid Res 43(12):2042–2048
20. Liou YB, Sheu MT, Liu DZ, Lin SY, Ho HO (2010) Quantitation of
ceramides in nude mouse skin by normal-phase liquid chromatogra-
phy and atmospheric pressure chemical ionization mass spectrome-
try. Anal Biochem 401(1):107–113
21. Thomas D, Eberle M, Schiffmann S, Zhang DD, Geisslinger G,
Ferreiros N (2013) Nano-LC-MS/MS for the quantitation of
ceramides in mice cerebrospinal fluid using minimal sample volume.
Talanta 116:912–918
22. Kasumov T, Huang H, Chung YM, Zhang R, McCullough AJ,
Kirwan JP (2010) Quantification of ceramide species in biological
samples by liquid chromatography electrospray ionization tandem
mass spectrometry. Anal Biochem 401(1):154–161
23. Jiang H, Hsu FF, Farmer MS, Peterson LR, Schaffer JE, Ory DS,
Jiang X (2013) Development and validation of LC-MS/MS method
for determination of very long acyl chain (C22:0 and C24:0)
ceramides in human plasma. Anal Bioanal Chem 405(23):7357–
7365
24. Farwanah H, Kolter T, Sandhoff K (2011) Mass spectrometric anal-
ysis of neutral sphingolipids: methods, applications, and limitations.
Biochim Biophys Acta 1811(11):854–860
25. Bui HH, Leohr JK, Kuo MS (2012) Analysis of sphingolipids in
extracted human plasma using liquid chromatography electrospray
ionization tandem mass spectrometry. Anal Biochem 423(2):187–
194
26. Eisinger K, Krautbauer S, Hebel T, Schmitz G, Aslanidis C, Liebisch
G, Buechler C (2014) Lipidomic analysis of the liver from high-fat
diet induced obese mice identifies changes in multiple lipid classes.
Exp Mol Pathol 97(1):37–43
27. Schuhmann K, Almeida R, Baumert M, Herzog R, Bornstein SR,
Shevchenko A (2012) Shotgun lipidomics on a LTQ Orbitrap mass
spectrometer by successive switching between acquisition polarity
modes. J Mass Spectrom 47(1):96–104
28. Legnini E, Orsini JJ, Muhl A, Johnson B, Dajnoki A, Bodamer OA
(2012) Analysis of acid sphingomyelinase activity in dried blood
spots using tandemmass spectrometry. Ann LabMed 32(5):319–323
29. Sanchez BA, Capote FP, Luque de Castro MD (2011) Targeted anal-
ysis of sphingoid precursors in human biofluids by solid-phase ex-
traction with in situ derivatization prior to mu-LC-LIF determination.
Anal Bioanal Chem 400(3):757–765
30. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction
and purification. Can J Biochem Physiol 37(8):911–917
31. Palmer K, Di Iulio F, Varsi AE, Gianni W, Sancesario G, Caltagirone
C, Spalletta G (2010) Neuropsychiatric predictors of progression
from amnestic-mild cognitive impairment to Alzheimer’s disease:
the role of depression and apathy. J Alzheimers Dis 20(1):175–183
32. Di Iulio F, Palmer K, Blundo C, Casini AR, GianniW, Caltagirone C,
Spalletta G (2010) Occurrence of neuropsychiatric symptoms and
psychiatric disorders in mild Alzheimer’s disease and mild cognitive
impairment subtypes. Int Psychogeriatr 22(4):629–640
33. Gu H, Liu G, Wang J, Aubry AF, Arnold ME (2014) Selecting the
correct weighting factors for linear and quadratic calibration curves
with least-squares regression algorithm in bioanalytical LC-MS/MS
assays and impacts of using incorrect weighting factors on curve
stability, data quality, and assay performance. Anal Chem 86(18):
8959–8966
34. van de Merbel NC (2008) Quantitative determination of endogenous
compounds in biological samples using chromatographic techniques.
Trends Anal Chem 27(10):924–933
35. Booth B, Arnold ME, DeSilva B, Amaravadi L, Dudal S, Fluhler E,
Gorovits B, Haidar SH, Kadavil J, Lowes S, Nicholson R, Rock M,
Skelly M, Stevenson L, Subramaniam S, Weiner R, Woolf E. (2014)
Workshop report: crystal city V-Quantitative bioanalytical method
validation and implementation: the 2013 revised FDA guidance.
AAPS journal. doi:10.1208/s12248-014-9696-2
36. Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003)
Strategies for the assessment of matrix effect in quantitative
bioanalytical methods based on HPLC-MS/MS. Anal Chem
75(13):3019–3030
37. Lan T, Bi H, Liu W, Xie X, Xu S, Huang H (2011) Simultaneous
determination of sphingosine and sphingosine 1-phosphate in biolog-
ical samples by liquid chromatography-tandem mass spectrometry. J
Chromatogr B Anal Technol Biomed Life Sci 879(7–8):520–526
38. Shaner RL, Allegood JC, Park H, Wang E, Kelly S, Haynes CA,
Sullards MC, Merrill AH Jr (2009) Quantitative analysis of
sphingolipids for lipidomics using triple quadrupole and quadrupole
linear ion trap mass spectrometers. J Lipid Res 50(8):1692–1707
39. Byrdwell WC, Perry RH (2006) Liquid chromatography with dual
parallel mass spectrometry and (31)P nuclear magnetic resonance
s p e c t r o s c o p y f o r a n a l y s i s o f s p h i n g omye l i n a n d
Rapid LC-MS/MS evaluation of 25 key sphingolipids and phosphosphingolipids 5197
dihydrosphingomyelin I. Bovine brain and chicken egg yolk. J
Chromatogr A 1133(1–2):149–171
40. Geis-Asteggiante L, Lehotay SJ, Lightfield AR, Dutko T, Ng C,
Bluhm L (2012) Ruggedness testing and validation of a practical
analytical method for >100 veterinary drug residues in bovinemuscle
by ultrahigh performance liquid chromatography-tandem mass spec-
trometry. J Chromatogr A 1258:43–54
41. Evseenko D, Latour B, Richardson W, Corselli M, Sahaghian A,
Cardinal S, Zhu Y, Chan R, Dunn B, Crooks GM (2013)
Lysophosphatidic acid mediates myeloid differentiation within the
human bone marrow microenvironment. PLoS One 8(5):e63718
42. Chen RF (1967) Removal of fatty acids from serum albumin by
charcoal treatment. J Biol Chem 242(2):173–181
43. Jones BR, Schultz GA, Eckstein JA, Ackermann BL (2012)
Surrogate matrix and surrogate analyte approaches for definitive
quantitation of endogenous biomolecules. Bioanalysis 4(19):2343–
2356
44. Chen S, Wu JT, Huang R (2012) Evaluation of surrogate matrices for
standard curve preparation in tissue bioanalysis. Bioanalysis 4(21):
2579–2587
45. Bowen CL, Kehler J, Evans CA (2010) Development and
validation of a sensitive and selective UHPLC-MS/MS meth-
od for simultaneous determination of both free and total
eicosapentaeonic acid and docosahexenoic acid in human
plasma. J Chromatogr B Anal Technol Biomed Life Sci
878(30):3125–3133
5198 A. Basit et al.
